Published 09/26/2024 1:36:00 p.m.

Sickle Cell Disease Drug Pulled From Global Markets

Summary by MedPage Today

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an imbalance in deaths among patients taking the drug. “The overall benefit of the drug no longer outweighs the risk in the approved sickle cell patient population,” the company announced on Wednesday, adding that the imbalance in […]

0 Articles

All

Left

Center

Right

rd.nl

Sickle cell disease drug off the market

The European Medicines Agency (EMA) wants the marketing authorisation for the sickle cell disease drug Oxbryta to be suspended as a precaution. There are concerns about complications and the EMA wants to wait for the results of an ongoing investigation into the drug. Manufacturer Pfizer has already stated that it is prepared to withdraw the drug from the market.

09/26/2024 4:07:50 p.m.·Apeldoorn, Netherlands

Read Full Article

Investor's Business Daily

Pfizer Stock Dips After Pulling Sickle Cell Drug, But Other Biotechs Rise

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

09/26/2024 2:20:29 p.m.

Read Full Article

MedPage Today

Sickle Cell Disease Drug Pulled From Global Markets

09/26/2024 1:16:02 p.m.·New York, United States

Read Full Article

GEN - Genetic Engineering and Biotechnology News…

Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials

Sixteen patients dosed with Pfizer’s sickle cell disease drug Oxbryta® (voxelotor) in a pair of clinical trials have died, European regulators disclosed hours before Pfizer said it was voluntarily withdrawing Oxbryta in the United States and all other markets where it has been approved. Pfizer cited deaths and vaso-occlusive crises occurring in patients given Oxbryta in clinical studies in announcing the voluntary withdrawal. The pharma giant al…

09/26/2024 10:52:32 a.m.

Read Full Article

biopharmadive.com

Pfizer to pull sickle cell drug from market, shut down trials

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S. in 2019.

09/26/2024 11:04:08 a.m.

Read Full Article

outsourcing-pharma.com

Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events.

09/26/2024 1:36:00 p.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left0Leaning Right1Center2Last Updated09/26/2024 8:39:11 p.m.Bias Distribution

67% Center

Bias Distribution

67% of the sources are Center

67% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Sickle Cell Disease Drug Pulled From Global Markets

0 Articles

0 Articles

Sickle cell disease drug off the market

Sickle cell disease drug off the market

Pfizer Stock Dips After Pulling Sickle Cell Drug, But Other Biotechs Rise

Pfizer Stock Dips After Pulling Sickle Cell Drug, But Other Biotechs Rise

Sickle Cell Disease Drug Pulled From Global Markets

Sickle Cell Disease Drug Pulled From Global Markets

Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials

Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials

Pfizer to pull sickle cell drug from market, shut down trials

Pfizer to pull sickle cell drug from market, shut down trials

Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns

Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics